University of British Columbia to Perform Clinical Study on the Cardiovascular and Cognitive Health Effects of Lexaria’s TurboCBDTM.
Lexaria Bioscience Corporation (CSE:LXX,OTCQB:LXRP) announces the world’s first clinical study on human volunteers of cannabidiol (CBD) within Lexaria’s high absorption TurboCBD™ product, to evaluate its effects on both cardiovascular health and cognitive function.
The study will have a double-blind and placebo controlled cross-over design measuring effects both after a single dose, and also after 7 days of daily dosing in 24 volunteers. The study hypothesises that, following TurboCBD™ supplementation, circulating CBD and nitric oxide will increase in both young and old participants; that glucose and blood pressure will remain stable; and that vascular function, and cognitive and physical exercise performance will improve to a greater extent in older participants. This research study has been approved by the Clinical Research Ethics Board at the University of British Columbia (“UBC”).
Professor Philip Ainslie, PhD, Co-Director of the Centre for Heart, Lung and Vascular Health, UBC Okanagan Campus, Kelowna, Canada, will be Principal Investigator of a team of co-investigators. UBC has consistently been ranked one of the top three universities in Canada, has over 62,000 students on two campuses, and is further considered one of the top research universities in the world. UBC has conducted several earlier studies in the cannabis sector, available for review at https://news.ubc.ca/tag/marijuana/
This advanced study will utilize the latest clinical evaluation techniques to provide pharma-level pharmacokinetic and pharmacodynamic performance data of TurboCBD™, including blood sampling, physiological measures, cognitive function testing, vascular function testing, and exercise performance testing. Outcome measurements will include circulating CBD and nitric oxide markers, plasma glucose, plasma insulin, blood pressure, heart rate, respiration, peripheral and brain blood flow and a battery of neuropsychological performance tests.
Dr. Philip Ainslie comments that, “This study gives us a great opportunity to obtain world class clinical data on the health and performance benefits of cannabidiol using Lexaria’s unique high absorption TurboCBD™ capsules in our state of the art laboratories. It is very exciting to be one of the first – if not the first – to conduct these kinds of studies in Canada. The potential implications of the study are far-reaching: from understanding the fundamental biological mechanism(s) of high absorption CBD in humans, to how this might influence blood vessel physiology and human performance. To quantify the pharmacokinetics of TurboCBD™ will allow us to make informed recommendations of optimum dosing in order to improve vascular health and performance throughout healthy aging. Once we understand these processes better, the applications to various clinical populations can then be explored. There are also many other CBD products from Lexaria that could also be explored in due course – the partnership with academia and Lexaria Biosciences is an excellent means to develop new collaborative ideas, products and positively impact society.”
“Lexaria is proud to be advancing our collective knowledge of the benefits of CBD specifically showcasing the benefits of Lexaria’s unique patented delivery technology,” said Chris Bunka, CEO of Lexaria Bioscience. “Results will advance Lexaria’s ability to custom design products that increase the leading performance our technology already offers to customers.”
Additional information will be released upon completion and interpretation of test results.
Lexaria Bioscience Corp. has developed and out-licenses its disruptive technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and was granted its first patents in the USA and in Australia related to edible forms of cannabinoids. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
For regular updates, connect with Lexaria on Facebook (https://www.facebook.com/Lexaria-Corp-106280556370600/) and Twitter (https://twitter.com/lexariacorp)
FOR FURTHER INFORMATION PLEASE CONTACT:
Lexaria Bioscience Corp.
Alex Blanchard, Communications Manager
This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements, including but not limited to: that any additional stock warrants or stock options will be exercised. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition, the patent application and approval process and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that existing capital is sufficient for the Company’s needs or that it will be able to raise additional capital. There is no assurance that Lexaria will successfully complete any other contemplated or existing technology license agreements; or that results from any studies will be favorable or in any way support future business activities of any kind. There is no assurance that any planned corporate activity, business venture, or initiative will be pursued, or if pursued, will be successful. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria Energy Foods, Ambarii, and ViPovaTM products are not intended to diagnose, treat, cure or prevent any disease.
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Click here to connect with Lexaria Bioscience Corporation (CSE:LXX,OTCQB:LXRP) to receive an Investor Presentation.
CanBud Distribution Corporation Closes 2M Second and Final Tranche of its Oversubscribed Private Placement Offering
CanBud Distribution Corporation (CSE: CBDX) (FSE: CD0) (“CanBud” or the “Corporation”) is pleased to announce that it has closed the final tranche of its oversubscribed non-brokered private placement for aggregate gross proceeds of approximately $4,730,000 (the “Offering”).
The Corporation issued a combined total of 39,409,346 units (each a “Unit“) at price of $0.12 per Unit, with each Unit comprised of one common share in the capital of the Corporation (each a “Common Share“) and one common share purchase warrant (each a “Warrant“). Each Warrant entitles the holder to purchase one additional Common Share at an exercise price of $0.22 within 24 months of the closing of the Offering (the “Warrant Term“), provided, however that if the closing price of the Common Shares on the Canadian Securities Exchange (the “CSE“) (or any such other stock exchange in Canada as the Common Shares may trade at the applicable time) is $0.25 or greater per Common Share for a period of five (5) consecutive trading days at any time after the closing date of the Offering, the Corporation may accelerate the Warrant Term such that the Warrants shall expire on the date which is 30 days following the date a press release is issued by the Corporation announcing the reduced warrant terms.
Thoughtful Brands Inc. (CSE:TBI)(FSE:1WZ1)(OTCQB:PEMTF) (the “Company” or “Thoughtful Brands) announces that the letter of intent with Franchise Cannabis Corp. (“FCC”), previously announced in January, has been terminated. The previously announced European joint venture with FCC will continue and allow the Company to launch and tailor its products to European consumer demands
In connection with termination of the merger transaction with FCC, the Company has agreed to pay FCC $100,000 in cash and to issue FCC 5,000,000 common shares of the Company at a deemed value of $0.05 per share. The common shares will be subject to a four-month-and-one-day statutory hold period in accordance with applicable securities laws.
Mergers and acquisitions (M&A) in cannabis space have helped boost the industry to new levels.
Strategic sale of non-core assets by Lobe adds non-dilutive capital and shareholder value
Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce, further to its press release dated February 23, 2021, that it has completed the sale to Ionic Brands Corp. (“Ionic Brands”) of Lobe’s non-core cannabis assets relating to Washington-based Cowlitz County Cannabis Cultivation Inc. (“Cowlitz”) held by Lobe’s subsidiary vendor, Green Star Biosciences Inc. (the “Transaction”).
Seattle Area Grocery Chain Metropolitan Market to Begin Carrying KOIOS and Fit Soda on March 22, 2021
Adding to its existing presence on the west coast of the United States, all five KOIOS™ flavours and all four Fit Soda™ flavours will be carried in Metropolitan Market stores beginning on Monday, March 22, 2021. Serving the Seattle-Tacoma area (population 3.87 million), Metropolitan Market is one of five chains under its parent firm Good Food Holdings, which has a total of 51 stores in California, Oregon, and Washington State.
Koios Beverage Corp. (CSE: KBEV; OTC: KBEVF) (the “Company” or “Koios”) is pleased to announce that beginning on Monday, March 22, 2021, Koios’ entire line of canned beverage products will be sold at all locations of Metropolitan Market, an urban format supermarket chain in the Seattle-Tacoma area of Washington State. In Q1 2021, the Company announced multiple placements of its beverage products with regional grocers in markets on the west coast of the United States including Market of Choice in Oregon Jensen’s in Southern California and major natural grocery chain Sprouts Farmers Market which has a substantial west coast presence with over one third of its locations (360+ stores across 23 states) in California as well as Washington State 1 . The Company has also recently announced other developments relating to its expansion efforts being undertaken in 2021 such as an in-house beverage canning facility and distribution agreements with regional and national wholesale partners.